Skip to main content
TipRanks
Go Ultimate75% OFF

Tissue Repair Ltd (TRP) AI Stock Analysis

7 Followers
AU:TRP

Tissue Repair Ltd

(ASX:TRP)

Select Model
Rating:47Neutral
Price Target:AUD 0.11â–¼(-1.82% Downside)
Action:upgraded
Date:11/06/26

Tissue Repair Ltd (AU:TRP) receives a low overall score of 47, primarily weighed down by its precarious financial situation. The company faces a severe liquidity risk with accelerating cash burn and lack of commercial revenue. While technical indicators show recent bullish momentum and the stock trades above key moving averages, heavily overbought conditions and deep unprofitability make it a high-risk, speculative investment.

Positive Factors
Debt-free balance sheetThe absence of debt reduces interest obligations, refinancing exposure, and lender-imposed constraints on capital allocation. This gives Tissue Repair greater financial flexibility than a similarly loss-making company with leverage, although continued losses still require careful funding management.
Negative Factors
Persistent operating lossesRecurring losses indicate that the current business model has not yet reached sustainable profitability. Deepening operating losses increase dependence on external funding and reduce the company’s ability to reinvest, absorb setbacks, or progress development activities without additional capital.

Tissue Repair Ltd (TRP) vs. iShares MSCI Australia ETF (EWA)

-75%-50%-25%0%25%50%AU:TRP-63.33%EWA+16.05%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
AUD 5.86M
Dividend Yield
―
Average Volume (3M)
95.35K
Price to Earnings (P/E)
-1.2
Beta (1Y)
1.24
Revenue Growth
32.22%
EPS Growth
-26.53%
Country
Australia
Employees
5
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

Tissue Repair Ltd Business Overview & Revenue Model

Company Description

Tissue Repair Ltd (TRP.AX) is an Australian clinical-stage biopharmaceutical firm dedicated to pioneering advanced solutions for wound care. The company's primary focus lies in developing treatments for persistent chronic wounds and enhancing recover...

Tissue Repair Ltd Financial Statement Overview

Summary

High-risk financial profile marked by an accelerating operating cash burn of $7.5M, widening net losses, and shrinking equity. While the lack of debt is positive, the short financial runway heavily pressures the score.

Income Statement

12Very Negative

Balance Sheet

38Negative

Cash Flow

10Very Negative
Financial statement breakdown
BreakdownTTMJun 2026Jun 2025Jun 2024Jun 2023Jun 2022
Income Statement
Total Revenue2.28M559.70K2.63M152.24K3,076171.92K
Gross Profit1.98M-1.80M2.63M150.51K428170.21K
EBITDA-4.81M-7.75M-4.72M-6.51M-5.14M-7.01M
Net Income-3.85M-5.36M-4.24M-4.14M-4.17M-6.84M
Balance Sheet
Total Assets12.44M10.34M14.57M19.39M22.38M25.90M
Cash, Cash Equivalents and Short-Term Investments8.29M4.77M12.32M16.44M21.40M25.46M
Total Debt000000
Total Liabilities607.50K1.57M662.53K1.35M497.35K559.64K
Stockholders Equity11.83M8.77M13.91M18.04M21.88M25.34M
Cash Flow
Free Cash Flow-5.70M-7.55M-4.12M-4.95M-4.26M-3.97M
Operating Cash Flow-5.27M-7.50M-3.70M-4.95M-4.26M-3.97M
Investing Cash Flow-432.20K-43.65K-421.67K-3,355-2,244-3,924
Financing Cash Flow0000021.36M

Tissue Repair Ltd Technical Analysis

Technical Analysis SentimentPositive
Last Price0.11

Price Trends

50DMA0.09Positive
100DMA0.09Positive
200DMA0.12Negative

Market Momentum

MACD0.01Positive
RSI54.82Neutral
STOCH17.65Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:TRP, the sentiment is Positive. The current price of 0.11 is above the 20-day moving average (MA) of 0.10, above the 50-day MA of 0.09, and below the 200-day MA of 0.12, indicating a neutral trend. The MACD of 0.01 indicates Positive momentum. The RSI at 54.82 is Neutral, neither overbought nor oversold. The STOCH value of 17.65 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AU:TRP.

Tissue Repair Ltd Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

AU:TRP against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
AU:MSBAU:MSB63NeutralAUD 2.45B-28.62-10.06%―555.67%49.08%
AU:ACRAU:ACR52NeutralAUD 5.82M-6.79-45.29%―290.25%92.05%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
AU:TRPAU:TRP47NeutralAUD 5.86M-1.24-52.04%―32.22%-26.53%
AU:OCCAU:OCC44NeutralAUD 155.26M-10.75-36.83%―51.07%-47.63%
AU:CMBAU:CMB39UnderperformAUD 10.60M-1.43-247.44%―-4.24%33.39%
AU:BOTAU:BOT38UnderperformAUD 22.10M-0.25-118.74%―499.47%31.20%

* Healthcare Sector Average

Performance Comparison

-50%0%AU:TRPAU:ACRAU:MSBAU:OCCAU:CMBAU:BOTDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
AU:TRP and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
AU:TRPTissue Repair Ltd0.11-0.18-62.07%
AU:ACRAcrux Limited0.01-0.01-37.50%
AU:MSBMesoblast Limited1.89-0.39-17.32%
AU:OCCOrthocell Ltd0.57-0.41-41.84%
AU:CMBRegeneus Ltd.0.36-0.15-29.41%
AU:BOTBotanix Pharmaceuticals Limited0.01-0.12-92.00%

Tissue Repair Ltd Corporate Events

Tissue Repair cancels shares in equal access buy-back

Oct 29, 2026

Tissue Repair Ltd has cancelled 7,198,783 ordinary fully paid shares under an equal access buy-back scheme, as notified in an Appendix 3H filing to the ASX dated October 30, 2026. The reduction in issued capital may improve capital management efficie...

Tissue Repair completes $935,000 off-market share buy-back

Oct 28, 2026

Tissue Repair Limited has completed its off-market equal access share buy-back, receiving valid applications from 172 eligible shareholders for 7,198,783 shares, below the buy-back limit of 7,692,307 shares. As a result, no scale-back will apply and...

Tissue Repair Completes Equal Access Share Buy-Back

Oct 28, 2026

Tissue Repair Ltd has completed an equal access share buy-back of its ordinary fully paid shares, repurchasing a total of 7,198,783 securities. The company paid aggregate consideration of approximately AUD 935,842 for the buy-back, marking the final...

Tissue Repair Sets November AGM as Chair Signals Support for Resolutions

Oct 22, 2026

Tissue Repair Limited has called its Annual General Meeting for 24 November 2026 in Sydney, giving shareholders the opportunity to vote on key matters affecting the company. The notice of meeting will be distributed mainly via electronic channels, wi...

Tissue Repair Outlines Equal Access Share Buy-Back Structure

Sep 28, 2026

Tissue Repair Ltd has released a buy-back offer booklet outlining an equal access off-market share buy-back open to eligible shareholders during a defined offer period. The company sets out how issuer-sponsored and CHESS holders, including trustees,...

Tissue Repair Sets 2026 AGM as Late-Stage Wound-Healing Pipeline Advances

Sep 23, 2026

Biotechnology developer Tissue Repair Limited, which specialises in second-generation wound healing therapies and is advancing its TR987 candidate into Phase 3 trials for chronic wounds, has outlined a broader pipeline including the TR Pro+ post-proc...

Tissue Repair Launches Equal Access Share Buy-Back on ASX

Sep 18, 2026

Tissue Repair Ltd has announced an equal access share buy-back of its ordinary fully paid shares listed on the ASX under code TRP. The move signals a capital management initiative that could enhance earnings per share and adjust the company’s capital...

Tissue Repair Shareholders Approve Delisting and Equal Access Buyback

Sep 18, 2026

Tissue Repair Limited, a Phase 3-stage biotechnology company, is developing second-generation wound healing therapies for chronic and acute wounds, alongside a post-procedure topical gel aimed at enhancing recovery and skin quality after cosmetic and...

Tissue Repair taps veteran medtech financier as new CFO

Sep 10, 2026

Tissue Repair Ltd has appointed experienced medtech and life sciences finance executive Mark Bouw as its new fractional Chief Financial Officer, effective 10 September 2026. Bouw, founder and CEO of specialist advisory firm Straterra Australia, bring...

Tissue Repair Brings TR Pro+ Distribution Back In-House in Australasia

Sep 2, 2026

Tissue Repair Limited has resumed direct distribution and management of its TR Pro+® hydrogel in the aesthetic market across Australia and New Zealand, bringing these activities back in-house to sit alongside its existing direct distribution in the m...

Tissue Repair Limited Confirms ASX-Aligned Governance for 2026

Aug 31, 2026

Tissue Repair Limited, an ASX-listed healthcare company focused on tissue repair solutions, operates under Australia’s corporate governance regime and provides investors with structured oversight of its board and management. The business maintains de...

Tissue Repair Widens Annual Loss as Net Tangible Assets Decline

Aug 31, 2026

Tissue Repair Ltd reported a marginal 0.4% decline in revenue to $3.21 million for the year ended 30 June 2026, while its net loss widened by 26.5% to $5.36 million, underscoring ongoing profitability challenges despite relatively stable top-line per...

Tissue Repair Plans ASX Delisting and $1m Share Buy-Back

Aug 17, 2026

Biotechnology developer Tissue Repair Ltd, which specialises in second-generation wound healing therapies, is progressing a pipeline led by its Phase 3 chronic wound candidate TR987 and supported by post-procedure gel TR Pro+ and other acute wound pr...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 06, 2026